Published in Cell on December 24, 2009
Tumor metastasis: molecular insights and evolving paradigms. Cell (2011) 10.34
Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling. J Clin Oncol (2011) 8.37
Intra-tumour heterogeneity: a looking glass for cancer? Nat Rev Cancer (2012) 6.82
Circulating tumor cells: approaches to isolation and characterization. J Cell Biol (2011) 6.54
A CXCL1 paracrine network links cancer chemoresistance and metastasis. Cell (2012) 4.89
Circulating tumor cell clusters are oligoclonal precursors of breast cancer metastasis. Cell (2014) 4.44
Breast cancer cells produce tenascin C as a metastatic niche component to colonize the lungs. Nat Med (2011) 4.25
Identification of a population of blood circulating tumor cells from breast cancer patients that initiates metastasis in a xenograft assay. Nat Biotechnol (2013) 4.11
Single-cell sequencing-based technologies will revolutionize whole-organism science. Nat Rev Genet (2013) 4.03
Tumors as organs: complex tissues that interface with the entire organism. Dev Cell (2010) 3.98
Single cell profiling of circulating tumor cells: transcriptional heterogeneity and diversity from breast cancer cell lines. PLoS One (2012) 3.74
Chemotaxis in cancer. Nat Rev Cancer (2011) 3.68
Selection of bone metastasis seeds by mesenchymal signals in the primary tumor stroma. Cell (2013) 3.33
Therapy-induced tumour secretomes promote resistance and tumour progression. Nature (2015) 3.07
Hypoxia and hypoxia-inducible factors: master regulators of metastasis. Clin Cancer Res (2010) 2.88
The seed and soil hypothesis revisited--the role of tumor-stroma interactions in metastasis to different organs. Int J Cancer (2011) 2.87
Tumor metastasis: moving new biological insights into the clinic. Nat Med (2013) 2.71
Macrophage binding to receptor VCAM-1 transmits survival signals in breast cancer cells that invade the lungs. Cancer Cell (2011) 2.64
Unravelling the complexity of metastasis - molecular understanding and targeted therapies. Nat Rev Cancer (2011) 2.64
IDO is a nodal pathogenic driver of lung cancer and metastasis development. Cancer Discov (2012) 2.56
Origins of metastatic traits. Cancer Cell (2013) 2.49
Tumor cell dissemination: emerging biological insights from animal models and cancer patients. Cancer Cell (2013) 2.08
Cancer stem cells in the development of liver cancer. J Clin Invest (2013) 2.06
Interleukin-6 in bone metastasis and cancer progression. Eur J Cancer (2010) 2.04
S100A8/A9 activate key genes and pathways in colon tumor progression. Mol Cancer Res (2011) 1.98
Critical research gaps and translational priorities for the successful prevention and treatment of breast cancer. Breast Cancer Res (2013) 1.92
Tumour angiogenesis regulation by the miR-200 family. Nat Commun (2013) 1.90
Metastatic stem cells: sources, niches, and vital pathways. Cell Stem Cell (2014) 1.88
Molecular mechanisms of metastasis in breast cancer--clinical applications. Nat Rev Clin Oncol (2010) 1.83
Proteoglycans in health and disease: new concepts for heparanase function in tumor progression and metastasis. FEBS J (2010) 1.78
Breast cancer - one term, many entities? J Clin Invest (2011) 1.72
Fascin is regulated by slug, promotes progression of pancreatic cancer in mice, and is associated with patient outcomes. Gastroenterology (2014) 1.71
Cancer genomics: one cell at a time. Genome Biol (2014) 1.70
Biology, detection, and clinical implications of circulating tumor cells. EMBO Mol Med (2014) 1.62
An analogy between the evolution of drug resistance in bacterial communities and malignant tissues. Nat Rev Cancer (2011) 1.58
Tracing the tumor lineage. Mol Oncol (2010) 1.56
Interactions with fibroblasts are distinct in Basal-like and luminal breast cancers. Mol Cancer Res (2010) 1.53
In vivo animal models for studying brain metastasis: value and limitations. Clin Exp Metastasis (2013) 1.52
AXL is an essential factor and therapeutic target for metastatic ovarian cancer. Cancer Res (2010) 1.50
Long-term outcome of patients with metastatic breast cancer treated with high-dose chemotherapy and transplantation of purified autologous hematopoietic stem cells. Biol Blood Marrow Transplant (2011) 1.49
Modeling metastasis in the mouse. Curr Opin Pharmacol (2010) 1.46
IL-6 trans-signaling licenses mouse and human tumor microvascular gateways for trafficking of cytotoxic T cells. J Clin Invest (2011) 1.46
Significance of heparanase in cancer and inflammation. Cancer Microenviron (2011) 1.46
Fascin Regulates Nuclear Movement and Deformation in Migrating Cells. Dev Cell (2016) 1.45
Selective gene-expression profiling of migratory tumor cells in vivo predicts clinical outcome in breast cancer patients. Breast Cancer Res (2012) 1.43
The initial hours of metastasis: the importance of cooperative host-tumor cell interactions during hematogenous dissemination. Cancer Discov (2012) 1.40
Tumor endothelin-1 enhances metastatic colonization of the lung in mouse xenograft models of bladder cancer. J Clin Invest (2010) 1.39
Molecular characterization of breast cancer CTCs associated with brain metastasis. Nat Commun (2017) 1.39
Cytokines, inflammation and colon cancer. Curr Cancer Drug Targets (2011) 1.38
Noncanonical TGF-β signaling during mammary tumorigenesis. J Mammary Gland Biol Neoplasia (2011) 1.38
Steps in prostate cancer progression that lead to bone metastasis. Int J Cancer (2011) 1.34
Clinical relevance and biology of circulating tumor cells. Breast Cancer Res (2011) 1.34
Targeting tumor cell motility to prevent metastasis. Adv Drug Deliv Rev (2011) 1.32
TRAIL-coated leukocytes that kill cancer cells in the circulation. Proc Natl Acad Sci U S A (2014) 1.31
Metastatic colonization by circulating tumour cells. Nature (2016) 1.31
Cell-matrix interactions in mammary gland development and breast cancer. Cold Spring Harb Perspect Biol (2010) 1.30
Phase I study of GC1008 (fresolimumab): a human anti-transforming growth factor-beta (TGFβ) monoclonal antibody in patients with advanced malignant melanoma or renal cell carcinoma. PLoS One (2014) 1.26
Aspirin as adjuvant therapy for colorectal cancer--reinterpreting paradigms. Nat Rev Clin Oncol (2012) 1.26
Circulating tumors cells as biomarkers: progress toward biomarker qualification. Cancer J (2011) 1.25
Piwil2 is expressed in various stages of breast cancers and has the potential to be used as a novel biomarker. Int J Clin Exp Pathol (2010) 1.24
Oncogenic β-catenin triggers an inflammatory response that determines the aggressiveness of hepatocellular carcinoma in mice. J Clin Invest (2012) 1.24
Current challenges for detection of circulating tumor cells and cell-free circulating nucleic acids, and their characterization in non-small cell lung carcinoma patients. What is the best blood substrate for personalized medicine? Ann Transl Med (2014) 1.24
N-myc downstream regulated gene 1 modulates Wnt-β-catenin signalling and pleiotropically suppresses metastasis. EMBO Mol Med (2012) 1.24
Toward a drug development path that targets metastatic progression in osteosarcoma. Clin Cancer Res (2014) 1.23
Whole-genome and multisector exome sequencing of primary and post-treatment glioblastoma reveals patterns of tumor evolution. Genome Res (2015) 1.22
Diverted total synthesis leads to the generation of promising cell-migration inhibitors for treatment of tumor metastasis: in vivo and mechanistic studies on the migrastatin core ether analog. J Am Chem Soc (2010) 1.19
Epigenetic regulation of cancer stem cells in liver cancer: current concepts and clinical implications. J Hepatol (2010) 1.16
Resection of the primary tumor improves survival in metastatic breast cancer by reducing overall tumor burden. Surgery (2013) 1.16
Disseminated breast cancer cells acquire a highly malignant and aggressive metastatic phenotype during metastatic latency in the bone. PLoS One (2012) 1.15
MYC gene amplification is often acquired in lethal distant breast cancer metastases of unamplified primary tumors. Mod Pathol (2011) 1.15
Isolation of tumorigenic circulating melanoma cells. Biochem Biophys Res Commun (2010) 1.13
Human 3D vascularized organotypic microfluidic assays to study breast cancer cell extravasation. Proc Natl Acad Sci U S A (2014) 1.13
Preoperative concurrent paclitaxel-radiation in locally advanced breast cancer: pathologic response correlates with five-year overall survival. Breast Cancer Res Treat (2010) 1.12
Aspirin, lysine, mifepristone and doxycycline combined can effectively and safely prevent and treat cancer metastasis: prevent seeds from gemmating on soil. Oncotarget (2015) 1.11
Is tail vein injection a relevant breast cancer lung metastasis model? J Thorac Dis (2013) 1.11
The two faces of IL-6 in the tumor microenvironment. Semin Immunol (2014) 1.10
Activation of MAPK pathways due to DUSP4 loss promotes cancer stem cell-like phenotypes in basal-like breast cancer. Cancer Res (2013) 1.08
Breast cancer stem cells: Multiple capacities in tumor metastasis. Cancer Lett (2014) 1.07
Circulating tumor cells in breast cancer: a tool whose time has come of age. BMC Med (2011) 1.07
Therapeutic strategies targeting cancer stem cells. Cancer Sci (2015) 1.07
Circulating tumor cells and DNA as liquid biopsies. Genome Med (2013) 1.06
Polyclonal breast cancer metastases arise from collective dissemination of keratin 14-expressing tumor cell clusters. Proc Natl Acad Sci U S A (2016) 1.05
Cytoplasmic p27 promotes epithelial-mesenchymal transition and tumor metastasis via STAT3-mediated Twist1 upregulation. Oncogene (2015) 1.04
Bone marrow-infiltrating human neuroblastoma cells express high levels of calprotectin and HLA-G proteins. PLoS One (2012) 1.03
Stat3 mediates expression of autotaxin in breast cancer. PLoS One (2011) 1.03
The primacy of β1 integrin activation in the metastatic cascade. PLoS One (2012) 1.03
Squamous cell carcinoma of the oral cavity and circulating tumour cells. World J Clin Oncol (2014) 1.02
Hypermutable DNA chronicles the evolution of human colon cancer. Proc Natl Acad Sci U S A (2014) 1.02
Circulating tumor cells in the diagnosis and management of pancreatic cancer. Biochim Biophys Acta (2012) 1.02
Epigenetic upregulation of HGF and c-Met drives metastasis in hepatocellular carcinoma. PLoS One (2013) 1.02
The genomic landscape and evolution of endometrial carcinoma progression and abdominopelvic metastasis. Nat Genet (2016) 1.01
Microenvironments dictating tumor cell dormancy. Recent Results Cancer Res (2012) 1.01
Biology and significance of circulating and disseminated tumour cells in colorectal cancer. Langenbecks Arch Surg (2012) 1.01
Personalized colon cancer care in 2010. Semin Oncol (2011) 1.01
The mathematics of cancer: integrating quantitative models. Nat Rev Cancer (2015) 1.00
Bone marrow as a reservoir for disseminated tumor cells: a special source for liquid biopsy in cancer patients. Bonekey Rep (2014) 0.99
Caught in the act: revealing the metastatic process by live imaging. Dis Model Mech (2013) 0.99
Epigenetics underpinning the regulation of the CXC (ELR+) chemokines in non-small cell lung cancer. PLoS One (2011) 0.99
The Tumor-Promoting Flow of Cells Into, Within and Out of the Tumor Site: Regulation by the Inflammatory Axis of TNFα and Chemokines. Cancer Microenviron (2011) 0.98
Inflammation and cancer. Nature (2002) 53.78
Angiogenesis in cancer and other diseases. Nature (2000) 28.28
New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer (2002) 24.71
Genes that mediate breast cancer metastasis to lung. Nature (2005) 19.85
A multigenic program mediating breast cancer metastasis to bone. Cancer Cell (2003) 16.86
Microenvironmental regulation of metastasis. Nat Rev Cancer (2008) 15.76
Metastasis: from dissemination to organ-specific colonization. Nat Rev Cancer (2009) 14.17
IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer. Cancer Cell (2009) 11.52
Paradoxical roles of the immune system during cancer development. Nat Rev Cancer (2006) 10.57
Oncogene-induced senescence relayed by an interleukin-dependent inflammatory network. Cell (2008) 9.22
Smoldering and polarized inflammation in the initiation and promotion of malignant disease. Cancer Cell (2005) 9.06
Selective events in the metastatic process defined by analysis of the sequential dissemination of subpopulations of a mouse mammary tumor. Cancer Res (1992) 9.02
The role of tumour-associated macrophages in tumour progression: implications for new anticancer therapies. J Pathol (2002) 8.27
Genes that mediate breast cancer metastasis to the brain. Nature (2009) 8.23
Molecular basis of metastasis. N Engl J Med (2008) 8.19
Systemic spread is an early step in breast cancer. Cancer Cell (2008) 7.91
Chemokine signaling via the CXCR2 receptor reinforces senescence. Cell (2008) 7.65
The interleukin-8 pathway in cancer. Clin Cancer Res (2008) 7.12
Mediators of vascular remodelling co-opted for sequential steps in lung metastasis. Nature (2007) 7.05
Tumor stroma and regulation of cancer development. Annu Rev Pathol (2006) 6.66
Dissecting the metastatic cascade. Nat Rev Cancer (2004) 6.32
Distinct organ-specific metastatic potential of individual breast cancer cells and primary tumors. J Clin Invest (2005) 6.10
Interleukin-6: from basic science to medicine--40 years in immunology. Annu Rev Immunol (2005) 5.27
The role of IL-6 and STAT3 in inflammation and cancer. Eur J Cancer (2005) 5.07
NF-kappaB promotes breast cancer cell migration and metastasis by inducing the expression of the chemokine receptor CXCR4. J Biol Chem (2003) 3.98
Systemic endocrine instigation of indolent tumor growth requires osteopontin. Cell (2008) 3.95
Lung metastasis genes couple breast tumor size and metastatic spread. Proc Natl Acad Sci U S A (2007) 3.92
VEGF as a key mediator of angiogenesis in cancer. Oncology (2005) 3.65
The leukocyte common antigen (CD45): a putative receptor-linked protein tyrosine phosphatase. Proc Natl Acad Sci U S A (1988) 3.57
Is cancer a disease of self-seeding? Nat Med (2006) 3.19
The role of chemokines in neutrophil biology. Front Biosci (2008) 3.10
Direct genetic analysis of single disseminated cancer cells for prediction of outcome and therapy selection in esophageal cancer. Cancer Cell (2008) 3.01
Significance of interleukin-6 (IL-6) in breast cancer (review). Breast Cancer Res Treat (2006) 2.89
Tumor cell-organ microenvironment interactions in the pathogenesis of cancer metastasis. Endocr Rev (2007) 2.78
Roles of fascin in cell adhesion and motility. Curr Opin Cell Biol (2004) 2.74
Interleukin-6 and its receptor in cancer: implications for translational therapeutics. Cancer (2007) 2.62
Increased serum concentration of angiogenic factors in malignant melanoma patients correlates with tumor progression and survival. J Clin Oncol (2001) 2.58
Roles of fascin in human carcinoma motility and signaling: prospects for a novel biomarker? Int J Biochem Cell Biol (2005) 2.39
IL-6 involvement in epithelial cancers. J Clin Invest (2007) 2.29
Fascin, a novel target of beta-catenin-TCF signaling, is expressed at the invasive front of human colon cancer. Cancer Res (2007) 2.26
Role of CXCL1 in tumorigenesis of melanoma. J Leukoc Biol (2002) 2.13
Dual role of macrophages in tumor growth and angiogenesis. J Leukoc Biol (2006) 2.08
Adaptation versus selection: the origins of metastatic behavior. Cancer Res (2007) 2.08
Interleukin-6 is a potent growth factor for ER-alpha-positive human breast cancer. FASEB J (2007) 1.99
Inflammatory cell infiltration of tumors: Jekyll or Hyde. Cancer Metastasis Rev (2007) 1.99
Importance of CXC chemokine receptor 2 in the homing of human peripheral blood endothelial progenitor cells to sites of arterial injury. Circ Res (2007) 1.49
Induction of haptotactic migration of melanoma cells by neutrophil activating protein/interleukin-8. Biochem Biophys Res Commun (1990) 1.48
Serum interleukin-8 (IL-8) is elevated in patients with metastatic melanoma and correlates with tumour load. Melanoma Res (1995) 1.28
The role of fascin in the migration and invasiveness of malignant glioma cells. Neoplasia (2008) 1.19
Molecular biology of keratinocyte differentiation. Environ Health Perspect (1989) 1.16
Keratinocyte proliferation, differentiation, and apoptosis--differential mechanisms of regulation by curcumin, EGCG and apigenin. Toxicol Appl Pharmacol (2007) 1.08
Interleukin-6 level in patients with colorectal cancer. Cancer Lett (2006) 1.04
Cytokines facilitate chemotactic motility of breast carcinoma cells. Breast Cancer (2000) 1.03
Tumor vasculature address book: identification of stage-specific tumor vessel zip codes by phage display. Cancer Cell (2003) 0.94
Mechanisms of TGF-beta signaling from cell membrane to the nucleus. Cell (2003) 25.94
Genes that mediate breast cancer metastasis to lung. Nature (2005) 19.85
Cancer metastasis: building a framework. Cell (2006) 19.67
A multigenic program mediating breast cancer metastasis to bone. Cancer Cell (2003) 16.86
Endogenous human microRNAs that suppress breast cancer metastasis. Nature (2008) 14.37
American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol (2007) 14.29
Metastasis: from dissemination to organ-specific colonization. Nat Rev Cancer (2009) 14.17
A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med (2003) 13.81
Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol (2003) 9.72
HER2 and response to paclitaxel in node-positive breast cancer. N Engl J Med (2007) 9.34
Cytostatic and apoptotic actions of TGF-beta in homeostasis and cancer. Nat Rev Cancer (2003) 8.35
Genes that mediate breast cancer metastasis to the brain. Nature (2009) 8.23
Molecular basis of metastasis. N Engl J Med (2008) 8.19
Representational oligonucleotide microarray analysis: a high-resolution method to detect genome copy number variation. Genome Res (2003) 7.86
Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med (2002) 7.84
TGFbeta primes breast tumors for lung metastasis seeding through angiopoietin-like 4. Cell (2008) 7.60
Genome-wide RNAi screen of Ca(2+) influx identifies genes that regulate Ca(2+) release-activated Ca(2+) channel activity. Proc Natl Acad Sci U S A (2006) 7.26
Epithelial-mesenchymal transitions: twist in development and metastasis. Cell (2004) 7.14
Mediators of vascular remodelling co-opted for sequential steps in lung metastasis. Nature (2007) 7.05
Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer. JAMA (2006) 6.45
Genetic determinants of cancer metastasis. Nat Rev Genet (2007) 6.38
Integration of Smad and forkhead pathways in the control of neuroepithelial and glioblastoma cell proliferation. Cell (2004) 6.35
Distinct organ-specific metastatic potential of individual breast cancer cells and primary tumors. J Clin Invest (2005) 6.10
c-Myc controls the balance between hematopoietic stem cell self-renewal and differentiation. Genes Dev (2004) 5.83
Adjuvant chemotherapy in older women with early-stage breast cancer. N Engl J Med (2009) 5.68
Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. J Natl Cancer Inst (2005) 5.55
Myc suppression of the p21(Cip1) Cdk inhibitor influences the outcome of the p53 response to DNA damage. Nature (2002) 5.25
Latent bone metastasis in breast cancer tied to Src-dependent survival signals. Cancer Cell (2009) 5.24
A CXCL1 paracrine network links cancer chemoresistance and metastasis. Cell (2012) 4.89
Lumpectomy plus tamoxifen with or without irradiation in women 70 years of age or older with early breast cancer. N Engl J Med (2004) 4.84
Nuclear CDKs drive Smad transcriptional activation and turnover in BMP and TGF-beta pathways. Cell (2009) 4.81
Genome-wide association study provides evidence for a breast cancer risk locus at 6q22.33. Proc Natl Acad Sci U S A (2008) 4.76
TGF-beta directly targets cytotoxic T cell functions during tumor evasion of immune surveillance. Cancer Cell (2005) 4.46
Roles of TGFbeta in metastasis. Cell Res (2009) 4.35
Breast cancer cells produce tenascin C as a metastatic niche component to colonize the lungs. Nat Med (2011) 4.25
Novel patterns of genome rearrangement and their association with survival in breast cancer. Genome Res (2006) 4.25
Breast cancer bone metastasis mediated by the Smad tumor suppressor pathway. Proc Natl Acad Sci U S A (2005) 4.20
Lung metastasis genes couple breast tumor size and metastatic spread. Proc Natl Acad Sci U S A (2007) 3.92
E2F4/5 and p107 as Smad cofactors linking the TGFbeta receptor to c-myc repression. Cell (2002) 3.87
WNT/TCF signaling through LEF1 and HOXB9 mediates lung adenocarcinoma metastasis. Cell (2009) 3.76
Beyond tumorigenesis: cancer stem cells in metastasis. Cell Res (2007) 3.63
Transforming growth factor beta signaling impairs Neu-induced mammary tumorigenesis while promoting pulmonary metastasis. Proc Natl Acad Sci U S A (2003) 3.61
A self-enabling TGFbeta response coupled to stress signaling: Smad engages stress response factor ATF3 for Id1 repression in epithelial cells. Mol Cell (2003) 3.57
Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study. J Clin Oncol (2008) 3.54
Adjuvant chemotherapy in older and younger women with lymph node-positive breast cancer. JAMA (2005) 3.43
Late extended adjuvant treatment with letrozole improves outcome in women with early-stage breast cancer who complete 5 years of tamoxifen. J Clin Oncol (2008) 3.40
Selection of bone metastasis seeds by mesenchymal signals in the primary tumor stroma. Cell (2013) 3.33
Hematopoiesis controlled by distinct TIF1gamma and Smad4 branches of the TGFbeta pathway. Cell (2006) 3.31
Activation of multiple proto-oncogenic tyrosine kinases in breast cancer via loss of the PTPN12 phosphatase. Cell (2011) 3.27
VCAM-1 promotes osteolytic expansion of indolent bone micrometastasis of breast cancer by engaging α4β1-positive osteoclast progenitors. Cancer Cell (2011) 3.23
Balancing BMP signaling through integrated inputs into the Smad1 linker. Mol Cell (2007) 3.23
Is cancer a disease of self-seeding? Nat Med (2006) 3.19
Tumor entrained neutrophils inhibit seeding in the premetastatic lung. Cancer Cell (2011) 2.96
Epigenetic expansion of VHL-HIF signal output drives multiorgan metastasis in renal cancer. Nat Med (2012) 2.95
Dependency of colorectal cancer on a TGF-β-driven program in stromal cells for metastasis initiation. Cancer Cell (2012) 2.94
C/EBPbeta at the core of the TGFbeta cytostatic response and its evasion in metastatic breast cancer cells. Cancer Cell (2006) 2.87
ID genes mediate tumor reinitiation during breast cancer lung metastasis. Proc Natl Acad Sci U S A (2007) 2.85
Combination of trastuzumab and tanespimycin (17-AAG, KOS-953) is safe and active in trastuzumab-refractory HER-2 overexpressing breast cancer: a phase I dose-escalation study. J Clin Oncol (2007) 2.80
Outcome of preventive surgery and screening for breast and ovarian cancer in BRCA mutation carriers. J Clin Oncol (2002) 2.80
Macrophage binding to receptor VCAM-1 transmits survival signals in breast cancer cells that invade the lungs. Cancer Cell (2011) 2.64
A FoxO-Smad synexpression group in human keratinocytes. Proc Natl Acad Sci U S A (2006) 2.60
ADAMTS1 and MMP1 proteolytically engage EGF-like ligands in an osteolytic signaling cascade for bone metastasis. Genes Dev (2009) 2.59
Origins of metastatic traits. Cancer Cell (2013) 2.49
Ubiquitin ligase Nedd4L targets activated Smad2/3 to limit TGF-beta signaling. Mol Cell (2009) 2.45
HSP90 inhibition is effective in breast cancer: a phase II trial of tanespimycin (17-AAG) plus trastuzumab in patients with HER2-positive metastatic breast cancer progressing on trastuzumab. Clin Cancer Res (2011) 2.43
Breast cancer methylomes establish an epigenomic foundation for metastasis. Sci Transl Med (2011) 2.33
Cyclooxygenase-2 is overexpressed in HER-2/neu-positive breast cancer: evidence for involvement of AP-1 and PEA3. J Biol Chem (2002) 2.29
The safety of dose-dense doxorubicin and cyclophosphamide followed by paclitaxel with trastuzumab in HER-2/neu overexpressed/amplified breast cancer. J Clin Oncol (2008) 2.28
Sorting out breast-cancer gene signatures. N Engl J Med (2007) 2.22
Heterogenic loss of the wild-type BRCA allele in human breast tumorigenesis. Ann Surg Oncol (2007) 2.19
A combined analysis of outcome following breast cancer: differences in survival based on BRCA1/BRCA2 mutation status and administration of adjuvant treatment. Breast Cancer Res (2003) 2.09
Six cycles of doxorubicin and cyclophosphamide or Paclitaxel are not superior to four cycles as adjuvant chemotherapy for breast cancer in women with zero to three positive axillary nodes: Cancer and Leukemia Group B 40101. J Clin Oncol (2012) 2.07
Long-term adjustment of survivors of early-stage breast carcinoma, 20 years after adjuvant chemotherapy. Cancer (2003) 2.06
Smad2 nucleocytoplasmic shuttling by nucleoporins CAN/Nup214 and Nup153 feeds TGFbeta signaling complexes in the cytoplasm and nucleus. Mol Cell (2002) 2.05
Nucleocytoplasmic shuttling of signal transducers. Nat Rev Mol Cell Biol (2004) 2.04
Direct binding of Smad1 and Smad4 to two distinct motifs mediates bone morphogenetic protein-specific transcriptional activation of Id1 gene. J Biol Chem (2001) 1.99
Efficacy of letrozole extended adjuvant therapy according to estrogen receptor and progesterone receptor status of the primary tumor: National Cancer Institute of Canada Clinical Trials Group MA.17. J Clin Oncol (2007) 1.93
Dynamic regulation of alternative splicing by silencers that modulate 5' splice site competition. Cell (2008) 1.91
Toxicity of older and younger patients treated with adjuvant chemotherapy for node-positive breast cancer: the Cancer and Leukemia Group B Experience. J Clin Oncol (2007) 1.85
MicroRNA-335 inhibits tumor reinitiation and is silenced through genetic and epigenetic mechanisms in human breast cancer. Genes Dev (2011) 1.85
NF-kappaB regulation of YY1 inhibits skeletal myogenesis through transcriptional silencing of myofibrillar genes. Mol Cell Biol (2007) 1.84